Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:9110055rdf:typepubmed:Citationlld:pubmed
pubmed-article:9110055lifeskim:mentionsumls-concept:C0027567lld:lifeskim
pubmed-article:9110055lifeskim:mentionsumls-concept:C0008976lld:lifeskim
pubmed-article:9110055lifeskim:mentionsumls-concept:C0114873lld:lifeskim
pubmed-article:9110055lifeskim:mentionsumls-concept:C0178602lld:lifeskim
pubmed-article:9110055lifeskim:mentionsumls-concept:C0243095lld:lifeskim
pubmed-article:9110055lifeskim:mentionsumls-concept:C1705187lld:lifeskim
pubmed-article:9110055lifeskim:mentionsumls-concept:C0857121lld:lifeskim
pubmed-article:9110055pubmed:issue1lld:pubmed
pubmed-article:9110055pubmed:dateCreated1997-5-8lld:pubmed
pubmed-article:9110055pubmed:abstractTextDoxazosin, as a mono-therapy, was studied in 28 patients with mild to severe hypertension over a period of 8 weeks. After a wash-out period of 2 weeks, doxazosin was started at a dose of 1 mg daily and increased gradually until the diastolic blood pressure fell to below 90 mm Hg or a maximum dose of 16 mg daily was reduced. Forty-three percent of the patients had good response with diastolic blood pressure falling to normal (< 90 mm Hg) or by more than 10 mm Hg whilst 68% of the patients had a reduction of greater than 5 mm Hg. Doxazosin reduced blood pressure without significant increase in heart rate and was, overall, well tolerated producing mild side effects not requiring withdrawal, or reduction in dosage of the drug in 6 cases. The effect of doxazosin on lipids showed a trend towards reduction of total cholesterol and increase in HDL, but these data need confirmation in a longer study in a larger population sample.lld:pubmed
pubmed-article:9110055pubmed:languageenglld:pubmed
pubmed-article:9110055pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9110055pubmed:citationSubsetIMlld:pubmed
pubmed-article:9110055pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9110055pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9110055pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9110055pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:9110055pubmed:statusMEDLINElld:pubmed
pubmed-article:9110055pubmed:monthMarlld:pubmed
pubmed-article:9110055pubmed:issn0309-3913lld:pubmed
pubmed-article:9110055pubmed:authorpubmed-author:SalakoL ALAlld:pubmed
pubmed-article:9110055pubmed:authorpubmed-author:WalkerOOlld:pubmed
pubmed-article:9110055pubmed:authorpubmed-author:SowunmiAAlld:pubmed
pubmed-article:9110055pubmed:issnTypePrintlld:pubmed
pubmed-article:9110055pubmed:volume25lld:pubmed
pubmed-article:9110055pubmed:ownerNLMlld:pubmed
pubmed-article:9110055pubmed:authorsCompleteYlld:pubmed
pubmed-article:9110055pubmed:pagination53-9lld:pubmed
pubmed-article:9110055pubmed:dateRevised2004-11-17lld:pubmed
pubmed-article:9110055pubmed:meshHeadingpubmed-meshheading:9110055-...lld:pubmed
pubmed-article:9110055pubmed:meshHeadingpubmed-meshheading:9110055-...lld:pubmed
pubmed-article:9110055pubmed:meshHeadingpubmed-meshheading:9110055-...lld:pubmed
pubmed-article:9110055pubmed:meshHeadingpubmed-meshheading:9110055-...lld:pubmed
pubmed-article:9110055pubmed:meshHeadingpubmed-meshheading:9110055-...lld:pubmed
pubmed-article:9110055pubmed:meshHeadingpubmed-meshheading:9110055-...lld:pubmed
pubmed-article:9110055pubmed:meshHeadingpubmed-meshheading:9110055-...lld:pubmed
pubmed-article:9110055pubmed:meshHeadingpubmed-meshheading:9110055-...lld:pubmed
pubmed-article:9110055pubmed:meshHeadingpubmed-meshheading:9110055-...lld:pubmed
pubmed-article:9110055pubmed:meshHeadingpubmed-meshheading:9110055-...lld:pubmed
pubmed-article:9110055pubmed:meshHeadingpubmed-meshheading:9110055-...lld:pubmed
pubmed-article:9110055pubmed:meshHeadingpubmed-meshheading:9110055-...lld:pubmed
pubmed-article:9110055pubmed:meshHeadingpubmed-meshheading:9110055-...lld:pubmed
pubmed-article:9110055pubmed:meshHeadingpubmed-meshheading:9110055-...lld:pubmed
pubmed-article:9110055pubmed:meshHeadingpubmed-meshheading:9110055-...lld:pubmed
pubmed-article:9110055pubmed:meshHeadingpubmed-meshheading:9110055-...lld:pubmed
pubmed-article:9110055pubmed:meshHeadingpubmed-meshheading:9110055-...lld:pubmed
pubmed-article:9110055pubmed:year1996lld:pubmed
pubmed-article:9110055pubmed:articleTitleOpen trial of doxazosin in hypertensive Africans: dose finding, efficacy and safety studies.lld:pubmed
pubmed-article:9110055pubmed:affiliationDepartment of Pharmacology and Therapeutics, University of Ibadan, Nigeria.lld:pubmed
pubmed-article:9110055pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:9110055pubmed:publicationTypeClinical Triallld:pubmed
pubmed-article:9110055pubmed:publicationTypeControlled Clinical Triallld:pubmed